August 11, 2008 – DiaMedica Inc. (TSX-V:DMA), a drug discovery and clinical development company focused on a novel approach to treating type 2 diabetes, announces enrollment of the first patient in the phase II proof of concept clinical trial with DM-99, the Company’s third drug candidate to enter phase II human trials. The single-blinded clinical trial being conducted in the European Union, will demonstrate DM-99’s effectiveness at controlling blood glucose levels in 40 type 2 diabetes patients with HbA1c levels over 7.5%, after they have consumed a standardized meal. Change in insulin and/or glucose levels is the study’s primary endpoint. Each patient will be tested for both the effects of treatment with DM-99 as well as a placebo, and will therefore serve as their own control in this cross over study. Results are expected at the end of 2008... DiaMedica's Press Release -
